1. Circulating Angiogenesis Biomarkers Are Associated With Disease Progression in Lung Adenocarcinoma 
Shaun Daly, MD, John C. Kubasiak, MD, Daniel Rinewalt, MD, Ravi Pithadia, MD, Sanjib Basu, PhD, Cristina Fhied, MS, Gabriela C. Lobato, BS, Christopher W. Seder, MD, Edward Hong, MD, William H. Warren, MD, Gary Chmielewski, MD, Michael J. Liptay, MD, Philip Bonomi, MD, Jeffrey A. Borgia, PhD 
The Annals of Thoracic Surgery 
Volume 98, Issue 6, Pages (December 2014)
DOI: /j.athoracsur
Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Representative box-and-whisker plots indicate distributions of angiogenesis biomarkers across the patient groups. Distributions of (A) hepatocyte growth factor (HGF), (B) endoglin, (C) vascular endothelial growth factor (VEGF)-C, and (D) VEGF-D are shown for the following groups: node negative disease (T1a-3N0M0; n = 69); locoregional lymph node involvement (node positive, T1a-4N1-2M0; n = 60); and disseminated disease (TxNxM1) or stage IV disease (n = 68). Age- and sex-adjusted significance by analysis of variance is indicated as 1 (p ≤ 0.05), 2 (p ≤ 0.01), and 3 (p ≤ 0.001), with actual values provided in Table 1. (Note: Circles represent extreme values and asterisks represent outliers; not all extreme and outlier values are displayed, to permit appropriate scaling of plots.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Kaplan-Meier survival curves illustrate clinical outcomes associated with selected biomarkers within the stage I cohort (T1a-2aN0M0). Kaplan-Meier curves are shown for disease-free survival for (A) vascular endothelial growth factor (VEGF)-C and (B) VEGF-D, and for overall survival with (C) angiopoietin-2 and (D) VEGF-D. Cutoff values and number of cases in each arm are indicated as well as the log rank p value. (A, solid line = VEGF-C ≤ 56.6 pg/mL, dashed line = VEGF-C > 56.6 pg/mL; B, solid line = VEGF-D ≤ 17.4 pg/mL, dashed line = VEGF-D > 17.4 pg/mL; C, solid line = angiopoietin-2 ≤ pg/ML, dashed line = angiopoietin > pg/mL; D, solid line = VEGF-D ≤ 216.3 pg/mL, dashed line = VEGF-D > 216.3 pg/mL.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

4. Fig 3
Kaplan-Meier survival curves illustrate clinical outcomes associated with selected biomarkers within the stage IV cohort (TxNxM1). Kaplan-Meier curves are shown for progression-free survival for (A) endothelin-1 and (B) leptin, or overall survival with (C) angiopoeitin-2 and (D) endothelin-1. Cutoff values and number of cases in each arm are indicated as well as the log-rank p value. (A, solid line = endothelin-1 ≤ 3.64 pg/mL, dashed line = endothelin-1 > 3.64 pg/mL; B, solid line = leptin ≤ 4.61 pg/mL, dashed line = leptin > 4.61 pg/mL; C, solid line = angiopoietin-2 ≤ 2396 pg/mL, dashed line = angiopoietin > 2396 pg/mL; D, solid line = endothelin-1 ≤ 3.64 pg/mL, dashed line = endothelin-1 > 3.64 pg/mL.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions